Azzad Asset Management Inc. ADV Cuts Stock Position in Abbott Laboratories $ABT

Azzad Asset Management Inc. ADV trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 46.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,987 shares of the healthcare product maker’s stock after selling 18,182 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Abbott Laboratories were worth $2,155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. Freemont Management S.A. boosted its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories in the fourth quarter worth $116,580,000. Danica Pension Livsforsikringsaktieselskab bought a new stake in Abbott Laboratories in the third quarter worth $185,640,000. Thrivent Financial for Lutherans raised its stake in Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Finally, Net Worth Advisory Group bought a new position in Abbott Laboratories during the fourth quarter valued at $1,366,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ABT shares. Bank of America dropped their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. dropped their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Raymond James Financial reduced their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Leerink Partners lowered their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.42.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $93.97 on Friday. The company has a 50 day simple moving average of $89.21 and a two-hundred day simple moving average of $103.24. The stock has a market cap of $163.69 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 1.63 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter last year, the company posted $1.09 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.